People · Operator
Named in public records as an officer, director or promoter · active 2009–2017 · Biotechnology, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Syros Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $296.1M | $2.6B | 2012 |
| Editas Medicine, Inc. | — | Biotechnology | Series D+ | $120.0M | $4.9B | 2015 |
| Aveo Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $98.2M | $263.2M | 2009 |
| Quanterix Corp | — | Other Technology | Series C | $71.8M | $194.1M | 2010 |
| Tetraphase Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $64.7M | $350.8M | 2009 |
Douglas Cole at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Douglas Cole on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Robert Nelsen | 1 | 22 |
| Kevin Bitterman | 1 | 15 |
| Amir Nashat | 1 | 14 |
| John Connolly | 1 | 14 |
| Paul Meister | 1 | 12 |
| Robert Weisskoff | 1 | 12 |
| Keith Crandell | 1 | 11 |
| Srinivas Akkaraju | 1 | 10 |
| Russell Hirsch | 1 | 10 |
| David Johnston | 1 | 8 |
| Lawrence Miller | 1 | 8 |
| Robert Higgins | 1 | 7 |
| Anthony Evnin | 1 | 6 |
| John G. Freund | 1 | 6 |
| Nicholas Galakatos | 1 | 6 |
| Vicki Sato | 1 | 6 |
| David Walt | 1 | 6 |
| John M. Connolly | 1 | 6 |
| Alexis Borisy | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.